Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors

Ann Gerd Thorsell, Torun Ekblad, Tobias Karlberg, Mirjam Löw, Ana Filipa Pinto, Lionel Trésaugues, Martin Moche, Michael Cohen, Herwig Schüler

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Selective inhibitors could help unveil the mechanisms by which inhibition of poly(ADP-ribose) polymerases (PARPs) elicits clinical benefits in cancer therapy. We profiled 10 clinical PARP inhibitors and commonly used research tools for their inhibition of multiple PARP enzymes. We also determined crystal structures of these compounds bound to PARP1 or PARP2. Veliparib and niraparib are selective inhibitors of PARP1 and PARP2; olaparib, rucaparib, and talazoparib are more potent inhibitors of PARP1 but are less selective. PJ34 and UPF1069 are broad PARP inhibitors; PJ34 inserts a flexible moiety into hydrophobic subpockets in various ADP-ribosyltransferases. XAV939 is a promiscuous tankyrase inhibitor and a potent inhibitor of PARP1 in vitro and in cells, whereas IWR1 and AZ-6102 are tankyrase selective. Our biochemical and structural analysis of PARP inhibitor potencies establishes a molecular basis for either selectivity or promiscuity and provides a benchmark for experimental design in assessment of PARP inhibitor effects.

Original languageEnglish (US)
Pages (from-to)1262-1271
Number of pages10
JournalJournal of Medicinal Chemistry
Volume60
Issue number4
DOIs
StatePublished - Feb 23 2017

Fingerprint

Tankyrases
Poly(ADP-ribose) Polymerases
ADP Ribose Transferases
Benchmarking
Research Design
Poly(ADP-ribose) Polymerase Inhibitors
Enzymes
Research
Neoplasms

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Thorsell, A. G., Ekblad, T., Karlberg, T., Löw, M., Pinto, A. F., Trésaugues, L., ... Schüler, H. (2017). Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors. Journal of Medicinal Chemistry, 60(4), 1262-1271. https://doi.org/10.1021/acs.jmedchem.6b00990

Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors. / Thorsell, Ann Gerd; Ekblad, Torun; Karlberg, Tobias; Löw, Mirjam; Pinto, Ana Filipa; Trésaugues, Lionel; Moche, Martin; Cohen, Michael; Schüler, Herwig.

In: Journal of Medicinal Chemistry, Vol. 60, No. 4, 23.02.2017, p. 1262-1271.

Research output: Contribution to journalArticle

Thorsell, AG, Ekblad, T, Karlberg, T, Löw, M, Pinto, AF, Trésaugues, L, Moche, M, Cohen, M & Schüler, H 2017, 'Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors', Journal of Medicinal Chemistry, vol. 60, no. 4, pp. 1262-1271. https://doi.org/10.1021/acs.jmedchem.6b00990
Thorsell, Ann Gerd ; Ekblad, Torun ; Karlberg, Tobias ; Löw, Mirjam ; Pinto, Ana Filipa ; Trésaugues, Lionel ; Moche, Martin ; Cohen, Michael ; Schüler, Herwig. / Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors. In: Journal of Medicinal Chemistry. 2017 ; Vol. 60, No. 4. pp. 1262-1271.
@article{227970f324a74702a0579d646ef7ec3c,
title = "Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors",
abstract = "Selective inhibitors could help unveil the mechanisms by which inhibition of poly(ADP-ribose) polymerases (PARPs) elicits clinical benefits in cancer therapy. We profiled 10 clinical PARP inhibitors and commonly used research tools for their inhibition of multiple PARP enzymes. We also determined crystal structures of these compounds bound to PARP1 or PARP2. Veliparib and niraparib are selective inhibitors of PARP1 and PARP2; olaparib, rucaparib, and talazoparib are more potent inhibitors of PARP1 but are less selective. PJ34 and UPF1069 are broad PARP inhibitors; PJ34 inserts a flexible moiety into hydrophobic subpockets in various ADP-ribosyltransferases. XAV939 is a promiscuous tankyrase inhibitor and a potent inhibitor of PARP1 in vitro and in cells, whereas IWR1 and AZ-6102 are tankyrase selective. Our biochemical and structural analysis of PARP inhibitor potencies establishes a molecular basis for either selectivity or promiscuity and provides a benchmark for experimental design in assessment of PARP inhibitor effects.",
author = "Thorsell, {Ann Gerd} and Torun Ekblad and Tobias Karlberg and Mirjam L{\"o}w and Pinto, {Ana Filipa} and Lionel Tr{\'e}saugues and Martin Moche and Michael Cohen and Herwig Sch{\"u}ler",
year = "2017",
month = "2",
day = "23",
doi = "10.1021/acs.jmedchem.6b00990",
language = "English (US)",
volume = "60",
pages = "1262--1271",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "4",

}

TY - JOUR

T1 - Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors

AU - Thorsell, Ann Gerd

AU - Ekblad, Torun

AU - Karlberg, Tobias

AU - Löw, Mirjam

AU - Pinto, Ana Filipa

AU - Trésaugues, Lionel

AU - Moche, Martin

AU - Cohen, Michael

AU - Schüler, Herwig

PY - 2017/2/23

Y1 - 2017/2/23

N2 - Selective inhibitors could help unveil the mechanisms by which inhibition of poly(ADP-ribose) polymerases (PARPs) elicits clinical benefits in cancer therapy. We profiled 10 clinical PARP inhibitors and commonly used research tools for their inhibition of multiple PARP enzymes. We also determined crystal structures of these compounds bound to PARP1 or PARP2. Veliparib and niraparib are selective inhibitors of PARP1 and PARP2; olaparib, rucaparib, and talazoparib are more potent inhibitors of PARP1 but are less selective. PJ34 and UPF1069 are broad PARP inhibitors; PJ34 inserts a flexible moiety into hydrophobic subpockets in various ADP-ribosyltransferases. XAV939 is a promiscuous tankyrase inhibitor and a potent inhibitor of PARP1 in vitro and in cells, whereas IWR1 and AZ-6102 are tankyrase selective. Our biochemical and structural analysis of PARP inhibitor potencies establishes a molecular basis for either selectivity or promiscuity and provides a benchmark for experimental design in assessment of PARP inhibitor effects.

AB - Selective inhibitors could help unveil the mechanisms by which inhibition of poly(ADP-ribose) polymerases (PARPs) elicits clinical benefits in cancer therapy. We profiled 10 clinical PARP inhibitors and commonly used research tools for their inhibition of multiple PARP enzymes. We also determined crystal structures of these compounds bound to PARP1 or PARP2. Veliparib and niraparib are selective inhibitors of PARP1 and PARP2; olaparib, rucaparib, and talazoparib are more potent inhibitors of PARP1 but are less selective. PJ34 and UPF1069 are broad PARP inhibitors; PJ34 inserts a flexible moiety into hydrophobic subpockets in various ADP-ribosyltransferases. XAV939 is a promiscuous tankyrase inhibitor and a potent inhibitor of PARP1 in vitro and in cells, whereas IWR1 and AZ-6102 are tankyrase selective. Our biochemical and structural analysis of PARP inhibitor potencies establishes a molecular basis for either selectivity or promiscuity and provides a benchmark for experimental design in assessment of PARP inhibitor effects.

UR - http://www.scopus.com/inward/record.url?scp=85013828471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013828471&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.6b00990

DO - 10.1021/acs.jmedchem.6b00990

M3 - Article

VL - 60

SP - 1262

EP - 1271

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 4

ER -